Available Evidence and Outcome of Off-Label Use of Rituximab in Clinical Practice

European Journal of Clinical Pharmacology - Germany
doi 10.1007/s00228-013-1518-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Off-Label Use of Rituximab in Dermatology: Pemphigus Treatment

Anais Brasileiros de Dermatologia
Dermatology
2013English

Systemic Lupus Erythematosus: Extent and Patterns of Off-Label Use of Rituximab for SLE

Nature Reviews Rheumatology
Rheumatology
2016English

Off-Label Use of Rituximab in Refractory Pediatric Rheumatic Diseases: A Single-Center Experience

Pediatric Rheumatology
ImmunologyPediatricsRheumatologyAllergyPerinatologyChild Health
2014English

Clinical Outcome Following Second-Generation Drug-Eluting Stent Use for Off-Label Versus On-Label Indications: Insights From the Two-Year Outcome of the TWENTE Trial

EuroIntervention
MedicineCardiovascular MedicineCardiology
2014English

Off-Label Use of Approved Drugs

Nature Reviews Clinical Oncology
Oncology
2009English

Methylphenidate Off-Label Use and Safety

SpringerPlus
Multidisciplinary
2014English

Evidence for the Off-Label Use of Methylphenidate for Cognitive Enhancement in Healthy Individuals

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Rituximab in Neurological Disease: Principles, Evidence and Practice

Practical Neurology
MedicineNeurology
2018English

Off-Label Use of Omalizumab in Pediatric Anaphylaxis

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy